Bibliographic Details
| Title: |
The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech). |
| Authors: |
Andries, Jessica1 (AUTHOR), Viranaicken, Wildriss1 (AUTHOR), Cordonin, Colette2 (AUTHOR), Herrscher, Charline1 (AUTHOR), Planesse, Cynthia3 (AUTHOR), Roquebert, Bénédicte4 (AUTHOR), Lagrange-Xelot, Marie5 (AUTHOR), El-Kalamouni, Chaker1 (AUTHOR), Meilhac, Olivier3 (AUTHOR), Mavingui, Patrick1 (AUTHOR), Couret, David3,6 (AUTHOR), Gadea, Gilles1,7 (AUTHOR), Despres, Philippe1 (AUTHOR) philippe.despres@univ-reunion.fr |
| Source: |
Scientific Reports. 4/21/2022, Vol. 12 Issue 1, p1-13. 13p. |
| Subject Terms: |
*SARS-CoV-2, *PEPTIDES, *COVID-19, *IMMUNE serums, *EPITOPES |
| Company/Entity: |
BIONTECH SE , PFIZER Inc. 001326495 PFE |
| Abstract: |
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine comirnaty is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in comirnaty-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from comirnaty vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine comirnaty. [ABSTRACT FROM AUTHOR] |
|
Copyright of Scientific Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
